Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904495 | 0.81 | SYK (0.47) | CNR2TRPV1NPC1RAB9A | |
| SCHEMBL16114340 | 0.81 | CYP2A6 (0.67) | CNR2CYP2A6HPGDSTRPV1NPC1 | |
| SCHEMBL13750542 | 0.78 | CYP2A6 (0.44) | CNR2CYP2A6HPGDSTRPV1PTGS2 | |
| SCHEMBL10035263 | 0.77 | CYP2A6 (0.61) | CNR2CYP2A6PTGS2NPC1RAB9A | |
| SCHEMBL4181890 | 0.76 | PTGS2 (0.57) | CNR2ADORA3HPGDSPTGS2PTGS1 | |
| SCHEMBL27876851 | 0.76 | CYP11B2 (0.43) | CNR2CYP2A6TRPV1 | |
| SCHEMBL904543 | 0.76 | CNR2 (0.50) | CNR2CYP2A6TRPV1 | |
| SCHEMBL10264753 | 0.76 | USP7 (0.50) | CNR2CYP2A6ADORA3NPSR1NPC1 | |
| SCHEMBL29311603 | 0.75 | SYK (0.47) | CNR2CYP2A6HPGDSPKM | |
| SCHEMBL4182641 | 0.75 | CNR2 (0.49) | CNR2TRPV1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | disclosed |
| CN-101128452-B | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA | 2012-11-21 | — | — | CN | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| CN-101128452-A | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA (KR) | 2008-02-20 | — | — | CN | disclosed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | disclosed |
| EP-1685109-A2 | AMIDE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197364-A1 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050192293-A1 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005034870-A2 | AMIDE COMPOUNDS AND ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005032493-A2 | AMIDE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | CNR2 123/4885CYP2A6 2469/4885ADORA3 532/4885 |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | CNR2 34/4885CYP2A6 2222/4885ADORA3 1105/4885 |
| US-20050197364-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | CNR2 123/4885CYP2A6 2469/4885ADORA3 532/4885 |
| US-20050192293-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | CNR2 123/4885CYP2A6 2469/4885ADORA3 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.